Evidence map›Paper›PMID 35263421›Full record

Trial reportThe Journal of infectious diseases2022

The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.

Ramla F Tanko, Rubina Bunjun, Smritee Dabee, Shameem Z Jaumdally, Maricianah Onono, Gonasagrie Nair, Thesla Palanee-Phillips, Rushil Harryparsad, Anna Ursula Happel, Hoyam Gamieldien and 10 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02550067 (A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02550067 nacompletednot on this map

A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs)

TypeinterventionalSponsorFHI 360Ran2015 to 2018Enrolled7,830ConditionsHIV, ContraceptionArmsDMPA, LNG, Copper IUD
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 6 countries.

Ramla F TankoInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-2650-8203
Rubina BunjunInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Smritee DabeeSeattle Children's Research Institute, Seattle, Washington, USA.
Shameem Z JaumdallyInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Maricianah OnonoKenya Medical Research Institute, Kisumu, Kenya.
Gonasagrie NairDesmond Tutu HIV Foundation, Cape Town, South Africa.
Thesla Palanee-PhillipsWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
Rushil HarryparsadInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Anna Ursula HappelInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Hoyam GamieldienInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Yamkela QumbeloInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Musalula SinkalaInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Caitlin W ScovilleUniversity of Washington, Seattle, Washington, USA.
Kate HellerUniversity of Washington, Seattle, Washington, USA.
Jared M BaetenUniversity of Washington, Seattle, Washington, USA.
Steven E BosingerEmory University, Atlanta, Georgia, USA.
Adam BurgenerCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, USA.
Renee HeffronUniversity of Washington, Seattle, Washington, USA.
Heather B JaspanInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Jo Ann S PassmoreInstitute of Infectious Disease and Molecular Medicine, Department of Pathology, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZAUniversity of Washington · USDesmond Tutu HIV Foundation · ZAEmory University · USKarolinska Institutet · SEKenya Medical Research Institute · KENational Health Laboratory Service · ZAUniversity of the Witwatersrand · ZA

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Effects of Hormonal Contraceptives on Genital Immunity and HIV SusceptibilityR01HD089831 · NICHD · UNIVERSITY OF WASHINGTON · PI HEFFRON, RENEE A., JASPAN, HEATHER BERYL · 2016 to 2020
$3.0M
NICHD NIH HHS R01 HD089831NIH HHS P51 OD011132
6 · The paper itself

Abstract

backgroundThe ECHO trial randomized women to intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG-implant), or copper intrauterine device (Cu-IUD). In a substudy of the ECHO trial, we tested the hypothesis that contraceptives influence genital inflammation by comparing cervicovaginal cytokine changes following contraception initiation. In addition, we compared cytokine profiles in women who acquired HIV (cases) versus those remaining HIV negative (controls).

methodsWomen (n = 251) from South Africa and Kenya were included. Twenty-seven cervicovaginal cytokines were measured by Luminex at baseline, and 1 and 6 months after contraceptive iTanko et alnitiation. In addition, cytokines were measured preseroconversion in HIV cases (n = 25) and controls (n = 100).

resultsAt 6 months after contraceptive initiation, women using Cu-IUD had increased concentrations of 25/27 cytokines compared to their respective baseline concentrations. In contrast, women initiating DMPA-IM and LNG-implant did not experience changes in cervicovaginal cytokines. Preseroconversion concentrations of IL-1β, IL-6, and TNF-α, previously associated with HIV risk, correlated with increased HIV risk in a logistic regression analysis, although not significantly after correcting for multiple comparisons. Adjusting for contraceptive arm did not alter these results.

conclusionsAlthough Cu-IUD use broadly increased cervicovaginal cytokine concentrations at 6 months postinsertion, these inflammatory changes were found not to be a significant driver of HIV risk. CLINICAL TRIALS REGISTRATION: NCT02550067.

Indexed as

Contraceptive Agents, FemaleGenitaliaContraceptionCytokinesFemaleHIV InfectionsHumansIntrauterine Devices, CopperLevonorgestrelMedroxyprogesterone AcetateContraceptive Agents, FemaleCytokinesLevonorgestrelMedroxyprogesterone AcetateCu-IUDDMPA-IMinflammationLNG-implantreproductive tract

Identifiers

PMID35263421
PMCPMC9470113
OpenAlexW4220996293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.